TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35083920

Group type: EXPERIMENTAL
Intervention: Hypnobirthing training
Number of subjects: 80
Study: 34632507

Group type: EXPERIMENTAL
Intervention: Helmet continuous positive airway pressure (hCPAP)
Number of subjects: 188

Group type: COMPARATOR
Intervention: High flow nasal cannula (HFNC)
Number of subjects: 188
Study: 32757736

Group type: EXPERIMENTAL
Intervention: Cosmetic camouflage (daily use for 12 weeks)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cosmetic camouflage (total follow up)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Cosmetic camouflage (Phase I)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 56
Study: 35633275

Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Solriamfetol
Number of subjects: 34
Study: 34217031

Group type: EXPERIMENTAL
Intervention: Maximal lean angle (n = 43)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Single lean angle (n = 26)
Number of subjects: 97
Study: 33272025

Group type: EXPERIMENTAL
Intervention: Home-based exercise monitored with telehealth
Number of subjects: 40

Group type: COMPARATOR
Intervention: Centre-based exercise
Number of subjects: 40
Study: 34763914

Group type: EXPERIMENTAL
Intervention: Calf health plan (INT)
Number of subjects: 3593

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 3593
Study: 33907131

Group type: EXPERIMENTAL
Intervention: Sphygmomanometer (group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Tourniquet (group B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no blocking)
Number of subjects: 120
Study: 34252573

Group type: EXPERIMENTAL
Intervention: HR-HPV negative women
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: HIV-positive women
Number of subjects: 2767

Group type: EXPERIMENTAL
Intervention: HIV-negative women
Number of subjects: 2767
Study: 32401072

Group type: EXPERIMENTAL
Intervention: Dance/movement therapy (DMT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 31
Study: 32781920

Group type: EXPERIMENTAL
Intervention: Temperate environment (18.3°C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Hot environment (36.3°C)
Number of subjects: 12
Study: 34315418

Group type: EXPERIMENTAL
Intervention: Scent dog detection of non-inactivated saliva samples
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scent dog detection of urine samples
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scent dog detection of sweat samples
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Scent dog detection of saliva samples
Number of subjects: 10
Study: 33319537

Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty (TKA) in the first stage and unicompartmental knee arthroplasty (UKA) in the second stage (observation group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Bilateral TKAs (control group)
Number of subjects: 24
Study: 35680431

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 259

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 259
Study: 34217660

Group type: EXPERIMENTAL
Intervention: Non-optimized CRT (NON-OPT group; n=89)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Electrocardiographically optimized CRT based on the fusion-optimized intervals (FOI group; n=91)
Number of subjects: 180
Study: 34061470

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 34266844

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (IVA) monotherapy with sham photodynamic therapy (n=80)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Aflibercept combined with reduced-fluence photodynamic therapy (RF-PDT) (n=80)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 160
Study: 33191854

Group type: EXPERIMENTAL
Intervention: Nomogram model integrated with inflammation-based factors
Number of subjects: 887
Study: 35188081

Group type: EXPERIMENTAL
Intervention: BADS-C total score
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Key Search Test
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Zoo Map Test 1
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: BADS-C subtests
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: BADS-C total score, Key Search Test, Zoo Map Test 1
Number of subjects: 74
Study: 34229860

Group type: EXPERIMENTAL
Intervention: Fentanyl 0.5 mcg.kg‐1 (Group F)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 124
Study: 32353057

Group type: EXPERIMENTAL
Intervention: R Shiny for implementing customizable surveys
Number of subjects: 0
Study: 35440941

Group type: EXPERIMENTAL
Intervention: Integrated nursing model of medical care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 120
Study: 34288617

Group type: EXPERIMENTAL
Intervention: Paired respondent data from the Canadian Health Measures Survey (CHMS)
Number of subjects: 0
Study: 34952447

Group type: EXPERIMENTAL
Intervention: Active anodal HD-tDCS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham anodal HD-tDCS
Number of subjects: 37
Study: 33166032

Group type: EXPERIMENTAL
Intervention: Propolis tablets at a dose of 250 mg twice daily for 4 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 35932536

Group type: EXPERIMENTAL
Intervention: Palm olein (IV64)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cocoa butter (CB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Palm olein (PO)
Number of subjects: 40
Study: 32228663

Group type: EXPERIMENTAL
Intervention: Doxycycline treatment added to standard limb hygiene for six weeks
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo treatment added to standard limb hygiene for six weeks
Number of subjects: 1800
Study: 34753083

Group type: EXPERIMENTAL
Intervention: Cognitive control treatment
Number of subjects: 44
Study: 32768403

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM) at 660 nm, 100 mW, 6 seconds, 2 J/cm2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dexamethasone (DXM) 4 mg every 8 hours for 3 days
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Dexamethasone (DXM)
Number of subjects: 20
Study: 34791669

Group type: EXPERIMENTAL
Intervention: Bouldering psychotherapy (BPT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 156
Study: 32781913

Group type: EXPERIMENTAL
Intervention: Soft shoe
Number of subjects: 848

Group type: COMPARATOR
Intervention: Hard shoe
Number of subjects: 848
Study: 35525050

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (no VR)
Number of subjects: 156
Study: 34430349

Group type: EXPERIMENTAL
Intervention: H1299 lung cancer cell lysates (10 mg protein/vaccine) with Iscomatrix™ adjuvant via deep intradermal injection q 4 weeks ×6
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: H1299 lung cancer cell lysates with Iscomatrix™ adjuvant
Number of subjects: 21

Group type: COMPARATOR
Intervention: Cyclophosphamide/celecoxib
Number of subjects: 21
Study: 32516765

Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender oil (steam inhalation)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 35570237

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 943

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943
Study: 32171318

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Mild moxibustion
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Warm-needling
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 360

Group type: COMPARATOR
Intervention: Celebrex treatment
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 360
Study: 36293867

Group type: EXPERIMENTAL
Intervention: KDL Active School Plan (KDL-ASP)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Conventional physical activities
Number of subjects: 596
Study: 33615328

Group type: EXPERIMENTAL
Intervention: RY Stop
Number of subjects: 499

Group type: COMPARATOR
Intervention: TR Band
Number of subjects: 499
Study: 33681738

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg followed by misoprostol 400 μg
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo followed by misoprostol 400 μg
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Mifepristone 600 mg
Number of subjects: 351

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study: 33183274

Group type: EXPERIMENTAL
Intervention: Mobilisation with movement (MWM) combined with exercise
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham MWM combined with exercise
Number of subjects: 70
Study: 35852859

Group type: EXPERIMENTAL
Intervention: FDM 3D-printed surgical guide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Stereolithographic guide
Number of subjects: 28
Study: 34414979

Group type: EXPERIMENTAL
Intervention: High-impact aerobics programme supplemented by pelvic floor muscle training for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 32
Study: 33752696

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) imaging
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Adenosine stress-perfusion CMR
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: CMR for diagnosing acute coronary syndrome (ACS)
Number of subjects: 51
Study: 35943928

Group type: EXPERIMENTAL
Intervention: FASD (force-activated separation device)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Control group (no FASD)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: FASD
Number of subjects: 367
Study: 34229364

Group type: EXPERIMENTAL
Intervention: DEHP-containing infusion sets warmed with blood-fluid warmers
Number of subjects: 30

Group type: COMPARATOR
Intervention: DEHP-free infusion sets warmed with blood-fluid warmers
Number of subjects: 30
Study: 32568220

Group type: EXPERIMENTAL
Intervention: Laparoscopic radical left pancreatectomy (LRLP)
Number of subjects: 1
Study: 36129364

Group type: EXPERIMENTAL
Intervention: Walk ’n Watch protocol
Number of subjects: 195

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 195
Study: 34091804

Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 99

Group type: COMPARATOR
Intervention: Conventional management (CM) protocol
Number of subjects: 99
Study: 32679728

Group type: EXPERIMENTAL
Intervention: 120 g/h carbohydrate intake (HIGH)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 90 g/h carbohydrate intake (MED)
Number of subjects: 26

Group type: COMPARATOR
Intervention: 60 g/h carbohydrate intake (LOW)
Number of subjects: 26
Study: 36199067

Group type: EXPERIMENTAL
Intervention: Acipimox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34044633

Group type: EXPERIMENTAL
Intervention: BCL2 polymorphisms and IL19 SNP rs2243188
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: BCL2 and IL19 susceptibility alleles
Number of subjects: 150
Study: 32055002

Group type: EXPERIMENTAL
Intervention: Androgen deprivation with cixutumumab
Number of subjects: 210

Group type: COMPARATOR
Intervention: Androgen deprivation alone (Control)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: High-risk disease
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: High-volume disease
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PSA >0.2 to ≤4.0 ng/mL
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: PSA >4.0 ng/mL
Number of subjects: 210
Study: 35995418

Group type: EXPERIMENTAL
Intervention: Synbiotic treatment (Lactobacillus acidophilus, Lactobacillus casei, and Bifidobacterium lactis, 32 billion colony forming units per day plus 3.2 g of inulin)
Number of subjects: 34
Study: 33620461

Group type: EXPERIMENTAL
Intervention: Forced-air warming (FAW), n=100
Number of subjects: 200
Study: 32353101

Group type: EXPERIMENTAL
Intervention: Preoperative Doppler ultrasound
Number of subjects: 228

Group type: COMPARATOR
Intervention: Clinical group (no Doppler ultrasound)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Doppler ultrasound group
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 228
Study: 616900538

Group type: EXPERIMENTAL
Intervention: Quince syrup (1 tablespoon/TDS) for 1 week
Number of subjects: 76

Group type: COMPARATOR
Intervention: Vitamin B6 tablets (20mg/TDS) for 1 week
Number of subjects: 76
Study: 36145196

Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D supplementation
Number of subjects: 2808

Group type: EXPERIMENTAL
Intervention: 3200 IU/day vitamin D supplementation
Number of subjects: 2808
Study: 33677449

Group type: EXPERIMENTAL
Intervention: rtfMRI Neurofeedback Training (NFT) in addition to standard care
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 52
Study: 32548286

Group type: EXPERIMENTAL
Intervention: Half stack segmentation method for calculating background parenchymal enhancement (BPE) from DCE-MRI
Number of subjects: 735

Group type: COMPARATOR
Intervention: Full stack segmentation method for calculating BPE from DCE-MRI
Number of subjects: 735

Group type: COMPARATOR
Intervention: Center 5 slices segmentation method for calculating BPE from DCE-MRI
Number of subjects: 735
Study: 35672955

Group type: EXPERIMENTAL
Intervention: Maralixibat
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 32270633

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied at Tianding (LI 17), Fengchi (GB 20), and Jiaji (EX-B 2, C3-C5), continuous wave, 10-20 Hz, 30 min each time, once a day, 6 times a week for 4 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group received Xingnao Kaiqiao acupuncture at Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Jiquan (HT 1), Chize (LU 5), and Weizhong (BL 40), needles sustained for 30 min, same treatment frequency as observation group
Number of subjects: 70
Study: 34419039

Group type: EXPERIMENTAL
Intervention: Orodental consultation requests due to dental problems
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Orodental consultation requests due to mucosal problems
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Age and consultation request relationship
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Referral to specialist due to oral problems
Number of subjects: 300
Study: 32738935

Group type: EXPERIMENTAL
Intervention: live attenuated intranasal pertussis vaccine BPZE1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: maternal immunisation
Number of subjects: 0
Study: 34881442

Group type: EXPERIMENTAL
Intervention: Hybrid surface macro-design implants (HS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional implants with moderately rough surface (RS)
Number of subjects: 40
Study: 33799064

Group type: EXPERIMENTAL
Intervention: Salix cupularis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microsites around Salix cupularis
Number of subjects: 0
Study: 34783683

Group type: EXPERIMENTAL
Intervention: Hypnosis
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Virtual Reality
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 32189665

Group type: EXPERIMENTAL
Intervention: Hydrogen-rich water (HW)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo water (PW)
Number of subjects: 8
Study: 35410121

Group type: EXPERIMENTAL
Intervention: Fremanezumab
Number of subjects: 1003
Study: 34464390

Group type: EXPERIMENTAL
Intervention: Fixed ankle joint condition
Number of subjects: 14

Group type: COMPARATOR
Intervention: Free ankle joint condition
Number of subjects: 14
Study: 32160801

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Apixaban 5 mg twice daily
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg twice daily
Number of subjects: 269

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 269
Study: 36424115

Group type: COMPARATOR
Intervention: Best practice advice (one session of physiotherapy, up to two optional additional advice sessions)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Progressive exercise (up to six sessions of physiotherapy)
Number of subjects: 61
Study: 34284552

Group type: EXPERIMENTAL
Intervention: Sufentanil IN 0.5 μg kg‐1
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Sufentanil IN 0.25 μg kg‐1
Number of subjects: 99

Group type: COMPARATOR
Intervention: IV midazolam 0.04 mg kg‐1 and IN 0.9% NaCl (placebo)
Number of subjects: 99
Study: 35958557

Group type: EXPERIMENTAL
Intervention: Marine long chain omega-3 polyunsaturated fatty acids (1.1 g EPA + 0.8 g DHA daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normal weight individuals)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (individuals living with obesity)
Number of subjects: 0
Study: 33636027

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) without enzalutamide (Cohort 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) and enzalutamide (Cohort 2)
Number of subjects: 30
Study: 32723718

Group type: EXPERIMENTAL
Intervention: Haptic nudge delivered via a wrist-worn wearable device
Number of subjects: 20

Group type: COMPARATOR
Intervention: No haptic nudge
Number of subjects: 20
Study: 33839115

Group type: EXPERIMENTAL
Intervention: Indoor air quality measurements of volatile organic compounds (VOCs) and inorganic gaseous pollutants using passive samplers over 7 days.
Number of subjects: 5017

Group type: EXPERIMENTAL
Intervention: Random forest model for estimating concentrations of VOCs and inorganic gaseous pollutants.
Number of subjects: 5017

Group type: EXPERIMENTAL
Intervention: Factors associated with indoor VOC and inorganic gaseous pollutant concentrations.
Number of subjects: 5017
Study: 33396846

Group type: EXPERIMENTAL
Intervention: Wearable cameras capturing snacking episodes
Number of subjects: 158
Study: 35580140

Group type: EXPERIMENTAL
Intervention: 12 home visits by a Community Health Worker (CHW) and a scheduled appointment to attend the smoking cessation program at the Public Health System (PHS)
Number of subjects: 328

Group type: COMPARATOR
Intervention: Scheduled appointment to attend the cessation program at the Public Health System (PHS)
Number of subjects: 328
Study: 34289903

Group type: EXPERIMENTAL
Intervention: ResidueFinder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MutationFinder
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ResidueFinder with streamlined regular expression (cut)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regular expressions tested using expanded F‐measure statistics
Number of subjects: 0
Study: 35968476

Group type: EXPERIMENTAL
Intervention: Isha yoga practice (3 minutes daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active comparator (15 minutes daily reading)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo comparator (15 minutes daily reading)
Number of subjects: 0
Study: 34815458

Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 58

Group type: COMPARATOR
Intervention: sham tDCS
Number of subjects: 58
Study: 33654007

Group type: EXPERIMENTAL
Intervention: Vascular imaging device
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fist clenching
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (no interventions)
Number of subjects: 135
Study: 32818346

Group type: EXPERIMENTAL
Intervention: Dexamethasone intraocular suspension 9%
Number of subjects: 414

Group type: COMPARATOR
Intervention: Topical prednisolone acetate 1%
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 414
Study: 32883328

Group type: EXPERIMENTAL
Intervention: SOC plus Tocilizumab (8mg/kg, infused over 60 minutes)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SOC plus Tocilizumab (4mg/kg, infused over 60 minutes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: SOC alone
Number of subjects: 90
Study: 35403793

Group type: EXPERIMENTAL
Intervention: Cotadutide (50‐300 μg, once‐daily subcutaneous)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 35002336

Group type: EXPERIMENTAL
Intervention: FlexDexTM with 3D visual output
Number of subjects: 40

Group type: COMPARATOR
Intervention: FlexDexTM with 2D visual output
Number of subjects: 40
Study: 35842199

Group type: EXPERIMENTAL
Intervention: Toripalimab
Number of subjects: 145

Group type: COMPARATOR
Intervention: High-Dose Interferon-α2b (HDI)
Number of subjects: 145
Study: 33449378

Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT) in addition to Treatment-As-Usual (TAU)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Functional Family Therapy (FFT)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 120
Study: 32418801

Group type: EXPERIMENTAL
Intervention: Intervention clusters (targeted clinician education, prediabetes clinician champion, custom electronic health record report)
Number of subjects: 2992

Group type: COMPARATOR
Intervention: Control clusters (standard care)
Number of subjects: 2992

Group type: EXPERIMENTAL
Intervention: Intervention clusters (adjusted for patient demographics and clinical variables)
Number of subjects: 2992
Study: 35999066

Group type: EXPERIMENTAL
Intervention: Dorsal bridge plating (30 patients)
Number of subjects: 60

Group type: COMPARATOR
Intervention: External fixation (30 patients)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 34436521

Group type: COMPARATOR
Intervention: Cisplatin (70 mg/m2 on day 1) and Gemcitabine (1000 mg/m2 on days 1 and 8 of a 21-day cycle)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cisplatin (60 mg/m2 on day 1), Gemcitabine (875 mg/m2 on days 1 and 8), and Berzosertib (90 mg/m2 on days 2 and 9 of a 21-day cycle)
Number of subjects: 87
Study: 33189801

Group type: EXPERIMENTAL
Intervention: Recharged NACP adhesive
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dentin control
Number of subjects: 2
Study: 32358417

Group type: EXPERIMENTAL
Intervention: KDB-Phaco
Number of subjects: 164

Group type: COMPARATOR
Intervention: iStent-Phaco
Number of subjects: 164